GLUE
Monte Rosa Therapeutics Inc
$5.62
Earnings Summary
Net Profits | $-35.18Mn |
Highlights
Monte Rosa Therapeutics Inc’s net profit fell -32.9% since last year same period to $-35.18Mn in the Q2 2023. On a quarterly growth basis, Monte Rosa Therapeutics Inc has generated -17.98% fall in its net profits since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Monte Rosa Therapeutics Inc post its latest quarter earnings
EPS Estimate Current Quarter | -0.68 |
EPS Estimate Current Year | -0.68 |
Highlights
Monte Rosa Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.68 - a 3.14% jump from last quarter’s estimates.
Monte Rosa Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.68.
Key Ratios
Key ratios of the Monte Rosa Therapeutics Inc post its Q3 2023 earnings
Earning Per Share (EPS) | 0 |
Highlights
Monte Rosa Therapeutics Inc’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2023. This indicates that the Monte Rosa Therapeutics Inc has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2023-05-11 | -0.65 | 0 | 100% |
2023-08-10 | -0.71 | 0 | 100% |
2023-11-09 | -0.68 | 0 | 100% |
₹0 US Stocks a/c Opening Fee